The codon context provides cis-acting immune evasion for the human papilloma virus (HPV) E6

  1. Justine Habault1
  1. 1Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, 75010 Paris, France
  2. 2Department of Medical Biosciences, Building 6M, Umeå University, 901 85 Umeå, Sweden
  3. 3Université de Brest; Inserm UMR1078; Établissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, F-29200 Brest, France
  4. 4RECAMO, Masaryk Memorial Cancer Institute, 65653 Brno, Czech Republic
  1. Corresponding author: justine.habault{at}inserm.fr
  1. Handling editor: Britt Glaunsinger

Abstract

Human papilloma viruses (HPV) are linked to cancers, but how virus-carrying tumor cells express HPV-encoded antigens without attracting the immune system is still poorly understood. Here, we show how low- and high-risk HPV types equally exploit a cis-acting mechanism to limit the translation of the E6 mRNA, reducing the production of antigenic peptide substrates for the major histocompatibility class I (MHC-I) pathway. Introducing particular combinations of preferable codons throughout the HPV-16 E6 mRNA promotes mRNA translation and production of antigenic peptide substrates in mammalian cells but has minimal impact on E6 synthesis in Saccharomyces cerevisiae. Using a gradual synonymous codon exchange, we identified a codon series with a significant effect on E6 translation rate. Unexpectedly, changing four nonpreferable codons to preferable codons in the wild-type sequence resulted in an ∼50% reduction in E6 expression. However, five additional changes to preferable codons further upstream shifted this inhibition to a strong induction of E6 expression, while they had no effect when introduced alone. These findings suggest a nuanced relationship between tRNA pools and translation rate, emphasizing how HPV uses codon usage to evade immune detection.

Keywords

  • Received January 13, 2025.
  • Accepted August 26, 2025.

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents